The Long Reach of the Retinoblastoma Tumor Suppressor Pathway
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 May 2024 | Viewed by 322
Special Issue Editors
Interests: cell cycle control in cancer as a therapeutic target; RB-tumor suppressor pathway in the progression of cancer Breast cancer and Pancreatic cancer genetics; defining rationally targeted therapeutic interventions for clinical use
Interests: understanding molecular mechanisms underlying tumor suppression mediated by the RB1 and TP53 genes; identifying genes involved in prostate cancer metastasis
Interests: intersection of tumor genetics with biological features of cancer
Interests: elucidation of the Retinoblastoma (RB) tumor suppressor protein function; study of the cell cycle and RB mediated chromatin organization; investigation of the mechanisms of action of CDK inhibitors in cancer therapy; defining therapeutic targets for patients who developed resistance to CDK4/6 inhibitors
Special Issue Information
Dear Colleagues,
The conventional retinoblastoma tumor suppressor (RB) pathway was defined over 25 years ago. While the subject has been intensely studied and plays a well-established role in cell cycle control, the biological impact of the RB-pathway has continued to expand. Recent studies have illustrated roles for RB in a spectrum of diverse, context-selective biology including cancer lineage states, metabolic programs, and immune responses. These findings have induced a re-appraisal of the mechanisms through which RB functions control gene expression beyond E2F transcription factors. Furthermore, it has become clear that the RB-pathway is a key determinant of tumor progression and therapeutic response. While CDK4/6 inhibitors directly impinge on RB, complex regulatory networks involving the RB-pathway are relevant for therapeutic responses or the emergence of acquired resistance in a number of distinct contexts.
This Special Issue explores new findings related to the breadth of the RB-pathway in tumor biology and therapy.
Prof. Dr. Erik Knudsen
Dr. David W. Goodrich
Dr. Agnieszka Witkiewicz
Dr. Ioannis Sanidas
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RB1
- E2F
- lineage-plasticity
- CDK4/6
- Cyclin
- metabolism
- chromatin
- CDK inhibitors
- senescence
